48,874
edits
Difference between revisions of "Programmed death-ligand 1"
Jump to navigation
Jump to search
no edit summary
| Line 1: | Line 1: | ||
'''Programmed death-ligand 1''', commonly abbreviated '''PD-L1''', is a protein with an important role in immune system regulation and [[cancer]]. | '''Programmed death-ligand 1''', commonly abbreviated '''PD-L1''', is a protein with an important role in immune system regulation and [[cancer]]. | ||
Normally, PD-L1 on cells binds with [[programmed cell death 1]] on the T lymphocytes.<ref name=pmid22658126/> | |||
PD-L1 is also known as '''CD274'''.<ref name=omim>{{OMIM|605402}}</ref> | |||
==General== | ==General== | ||
*[[IHC]] testing using a PD-L1 antibody (demonstrating positive tumour cells) predicts response to anti-PD-L1 drugs.<ref name=pmid26970723/> | *[[IHC]] testing using a PD-L1 antibody (demonstrating positive tumour cells) predicts response to anti-PD-L1 drugs.<ref name=pmid26970723/> | ||
==Background== | ===Background=== | ||
Cytotoxic T cell activation is driven by two sets of receptors:<ref>{{Cite journal | last1 = Ribas | first1 = A. | title = Tumor immunotherapy directed at PD-1. | journal = N Engl J Med | volume = 366 | issue = 26 | pages = 2517-9 | month = Jun | year = 2012 | doi = 10.1056/NEJMe1205943 | PMID = 22658126 }}</ref> | Cytotoxic T cell activation is driven by two sets of receptors:<ref name=pmid22658126>{{Cite journal | last1 = Ribas | first1 = A. | title = Tumor immunotherapy directed at PD-1. | journal = N Engl J Med | volume = 366 | issue = 26 | pages = 2517-9 | month = Jun | year = 2012 | doi = 10.1056/NEJMe1205943 | PMID = 22658126 }}</ref> | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
! Function | ! Function | ||